ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug

For some 15 years, a combination of drugs referred to as ABVD has been the standard of care to treat Hodgkin lymphoma. But that may soon change based in part on trial data from Seagen and Takeda’s lymphoma drug Adcetris.